Fig 1: rTcpC treatment leads to accumulation of PAD4 in proteasomes.a Dynamic observation of co-localization of PAD4 with PSMD2 by confocal microscopy. Scale bar = 5 µm. b Enlarged image of the co-localization in a at 210 min. Scale bar = 2 µm. Confocal microscopy images are representative of three independent experiments from three donors’ neutrophils, n = 3. c Percent and FI of co-localization were analyzed by ImageJ software. Mean ± SD of three independent experiments as described in a were shown. p < 0.05 and p < 0.01 compared with the group at 0 min. d Dynamic observation of co-localization of PAD4 with PSMD2 in the presence of MG-132 by confocal microscopy. Scale bar = 5 µm. e Enlarged image of the co-localization in d at 210 min. Scale bar = 2 µm. Confocal microscopy images are representative of three independent experiments from three donors’ neutrophils, n = 3. f Percent and FI of co-localization were analyzed by ImageJ software. Mean ± SD of three independent experiments as described in d were shown. p < 0.05 and p < 0.01 compared with the group at 0 min. p-values were derived by Dunnett test. Source data for panel c and f are provided in the separate Source Data file.
Supplier Page from Abcam for Anti-Proteasome 26S S2/PSMD2 antibody